A phase I/II study of 153 Sm EDTMP (Quadramet TM) [samarium 153-SM lexidronam] and PS-341 (Velcade RM) [bortezomib] in patients with relapsed or refractory multiple myeloma
Phase of Trial: Phase I/II
Latest Information Update: 10 May 2011
At a glance
- Drugs Bortezomib; Samarium-153-SM-lexidronam
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 02 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Feb 2009 Phase I results were published in Clinical Cancer Research, according to a EUSAPharma media release.
- 01 Feb 2007 New trial record.